24 results on '"Newman, Lisa A"'
Search Results
2. MYB misexpression links the spatial control of lignification with photomorphogenesis
- Author
-
Newman, Lisa J.
- Subjects
572.8 ,Molecular mechanisms ,Xylem foundation - Published
- 2001
3. Breast Cancer Disparities Through the Lens of the COVID-19 Pandemic.
- Author
-
Newman, Lisa, Newman, Lisa, Fejerman, Laura, Pal, Tuya, Mema, Eralda, McGinty, Geraldine, Cheng, Alex, Levy, Mia, Momoh, Adeyiza, Troester, Melissa, Schneider, Bryan, McNeil, Lorna, Davis, Melissa, Babagbemi, Kemi, Hunt, Kelly, Newman, Lisa, Newman, Lisa, Fejerman, Laura, Pal, Tuya, Mema, Eralda, McGinty, Geraldine, Cheng, Alex, Levy, Mia, Momoh, Adeyiza, Troester, Melissa, Schneider, Bryan, McNeil, Lorna, Davis, Melissa, Babagbemi, Kemi, and Hunt, Kelly
- Abstract
Purpose of reviewThe emergency medicine and critical care needs of the COVID-19 pandemic forced a sudden and dramatic disruption of cancer screening and treatment programs in the USA during the winter and spring of 2020. This review commentary addresses the impact of the pandemic on racial/ethnic minorities such as African Americans and Hispanic-Latina Americans, with a focus on factors related to breast cancer.Recent findingsAfrican Americans and Hispanic-Latina Americans experienced disproportionately higher morbidity and mortality from COVID-19; many of the same socioeconomic and tumor biology/genetic factors that explain breast cancer disparities are likely to account for COVID-19 outcome disparities.SummaryThe breast cancer clinical and research community should partner with public health experts to ensure participation of diverse patients in COVID-19 treatment trials and vaccine programs and to overcome COVID-19-related breast health management delays that are likely to have been magnified among African Americans and Hispanic-Latina Americans.
- Published
- 2021
4. Cancer health disparities in racial/ethnic minorities in the United States.
- Author
-
Zavala, Valentina A, Zavala, Valentina A, Bracci, Paige M, Carethers, John M, Carvajal-Carmona, Luis, Coggins, Nicole B, Cruz-Correa, Marcia R, Davis, Melissa, de Smith, Adam J, Dutil, Julie, Figueiredo, Jane C, Fox, Rena, Graves, Kristi D, Gomez, Scarlett Lin, Llera, Andrea, Neuhausen, Susan L, Newman, Lisa, Nguyen, Tung, Palmer, Julie R, Palmer, Nynikka R, Pérez-Stable, Eliseo J, Piawah, Sorbarikor, Rodriquez, Erik J, Sanabria-Salas, María Carolina, Schmit, Stephanie L, Serrano-Gomez, Silvia J, Stern, Mariana C, Weitzel, Jeffrey, Yang, Jun J, Zabaleta, Jovanny, Ziv, Elad, Fejerman, Laura, Zavala, Valentina A, Zavala, Valentina A, Bracci, Paige M, Carethers, John M, Carvajal-Carmona, Luis, Coggins, Nicole B, Cruz-Correa, Marcia R, Davis, Melissa, de Smith, Adam J, Dutil, Julie, Figueiredo, Jane C, Fox, Rena, Graves, Kristi D, Gomez, Scarlett Lin, Llera, Andrea, Neuhausen, Susan L, Newman, Lisa, Nguyen, Tung, Palmer, Julie R, Palmer, Nynikka R, Pérez-Stable, Eliseo J, Piawah, Sorbarikor, Rodriquez, Erik J, Sanabria-Salas, María Carolina, Schmit, Stephanie L, Serrano-Gomez, Silvia J, Stern, Mariana C, Weitzel, Jeffrey, Yang, Jun J, Zabaleta, Jovanny, Ziv, Elad, and Fejerman, Laura
- Abstract
There are well-established disparities in cancer incidence and outcomes by race/ethnicity that result from the interplay between structural, socioeconomic, socio-environmental, behavioural and biological factors. However, large research studies designed to investigate factors contributing to cancer aetiology and progression have mainly focused on populations of European origin. The limitations in clinicopathological and genetic data, as well as the reduced availability of biospecimens from diverse populations, contribute to the knowledge gap and have the potential to widen cancer health disparities. In this review, we summarise reported disparities and associated factors in the United States of America (USA) for the most common cancers (breast, prostate, lung and colon), and for a subset of other cancers that highlight the complexity of disparities (gastric, liver, pancreas and leukaemia). We focus on populations commonly identified and referred to as racial/ethnic minorities in the USA-African Americans/Blacks, American Indians and Alaska Natives, Asians, Native Hawaiians/other Pacific Islanders and Hispanics/Latinos. We conclude that even though substantial progress has been made in understanding the factors underlying cancer health disparities, marked inequities persist. Additional efforts are needed to include participants from diverse populations in the research of cancer aetiology, biology and treatment. Furthermore, to eliminate cancer health disparities, it will be necessary to facilitate access to, and utilisation of, health services to all individuals, and to address structural inequities, including racism, that disproportionally affect racial/ethnic minorities in the USA.
- Published
- 2021
5. Outcome of African‐American compared to White‐American patients with early‐stage breast cancer, stratified by phenotype
- Author
-
Lehrberg, Anna, Davis, Melissa B., Baidoun, Fadi, Petersen, Lindsay, Susick, Laura, Jenkins, Brittany, Chen, Yalei, Ivanics, Tommy, Rakitin, Ilya, Bensenhaver, Jessica, Proctor, Erica, Nathanson, Saul David, Newman, Lisa A., Lehrberg, Anna, Davis, Melissa B., Baidoun, Fadi, Petersen, Lindsay, Susick, Laura, Jenkins, Brittany, Chen, Yalei, Ivanics, Tommy, Rakitin, Ilya, Bensenhaver, Jessica, Proctor, Erica, Nathanson, Saul David, and Newman, Lisa A.
- Published
- 2021
- Full Text
- View/download PDF
6. Tumor and immune cell profiling in breast cancer using highly multiplexed imaging mass cytometry single-cell technology demonstrates tumor heterogeneity and immune phenotypic abnormality in Ethiopian women
- Author
-
Bekele, Maheteme, Jibril, Aisha, Seifu, Daniel, Abebe, Markos, Bekele, Abebe, Tigneh, Wondemagegnhu, Bokretsion, Yonas, Karlsson, Christina, Karlsson, Mats, Martini, Rachel, Elemento, Olivier, Yates, Clayton, Ginter, Paula, Newman, Lisa, Davis, Melissa, Gebregzabher, Endale Hadgu, Bekele, Maheteme, Jibril, Aisha, Seifu, Daniel, Abebe, Markos, Bekele, Abebe, Tigneh, Wondemagegnhu, Bokretsion, Yonas, Karlsson, Christina, Karlsson, Mats, Martini, Rachel, Elemento, Olivier, Yates, Clayton, Ginter, Paula, Newman, Lisa, Davis, Melissa, and Gebregzabher, Endale Hadgu
- Abstract
Background: Tumor heterogeneity represents a complex challenge to cancer treatment, disease recurrence, and patient survival. Imaging mass cytometry (IMC) is an emerging proteomic tool for cancer profiling in tumor tissue samples. IMC enables digital image analysis by multiplexed immunostaining of cells and proteins within tissue and preserves spatial relations within tumor environment. We have applied IMC based approach to study the heterogeneity of invasive breast carcinoma protein expression pattern in formalin fixed paraffin embedded tissues. Methods: A total of 10 region of interest (ROI) derived from 5 patients with primary invasive breast carcinoma representing three molecular subclasses (HR+/HER2-,HER2+/HR- and TNBC) were stained with a 30-marker IMC metal labeled antibody panel (α-SMA, EGFR, p53, CD33, CD16, CD163, CD11b, PDL1, CD31, CD45, D44,Vimentin, FoxP3, CD4, ECadherin, CD68, CD20, CD8a, Cytokeratin7, PD1, GranzymeB, Ki67, ColTypeI, CD3, CD45RO, HLADR, DARC & CD11c). Tissue imaging was done by quantifying the abundance of bound antibody with a Hyperion IMC. MCD Viewer was used for visualization purpose and to export raw 16-bit tiff images for segmentation on CellProfiler. Segmentation masks were combined with the individual tiff files to extract single-cell information from each individual image. HistoCAT was applied to perform unbiased clustering of cell populations using the PhenoGraph algorithm and clustered cell populations was overlaid on t-SNE plot. The relative marker expression was used to generate heat-maps and each cluster was manually assigned a phenotype based on its expression profile. Results: The t-SNE generated from each ROI revealed different distinct cell populations and we report the presence of diverse tumor and immune cell populations in our samples. The (min, max) number of PhenoGraph clustered tumor cell populations in HR+/HER2-, HER2+ and TNBC Cases were (5,8) (7,9) and (5,7) respectively. Similarly, the (min, max) number o
- Published
- 2020
- Full Text
- View/download PDF
7. Evaluation of a Multidisciplinary Team Approach for Generating Survivorship Care Plan Treatment Summaries in Patients With Breast Cancer
- Author
-
Ivanics, Tommy, Proctor, Erica, Chen, Yalei, Ali, Haythem, Severson, Dawn, Nasser, Hassan, Colbert, Sonja, Susick, Laura, Walker, Eleanor, Petersen, Lindsay, Bensenhaver, Jessica, Loutfi, Randa, Nathanson, S. David, Newman, Lisa A., Ivanics, Tommy, Proctor, Erica, Chen, Yalei, Ali, Haythem, Severson, Dawn, Nasser, Hassan, Colbert, Sonja, Susick, Laura, Walker, Eleanor, Petersen, Lindsay, Bensenhaver, Jessica, Loutfi, Randa, Nathanson, S. David, and Newman, Lisa A.
- Published
- 2019
- Full Text
- View/download PDF
8. Queer Communion : Ron Athey
- Author
-
Jones, Amelia, Campbell, Andy, Teasley, Lisa, Rice, Karen Gonzalez, Hilton, Leon J., Newman, Lisa, Padilla, Cesar, Katz, Jonathan D., Jones, Amelia, Campbell, Andy, Teasley, Lisa, Rice, Karen Gonzalez, Hilton, Leon J., Newman, Lisa, Padilla, Cesar, and Katz, Jonathan D.
- Abstract
"Ron Athey is one of the most important, prolific, and influential performance artists of the past four decades. A singular example of lived creativity, his radical performances are odds with the art worlds and art marketplaces that have increasingly dominated contemporary art and performance art over the period of his career. Queer Communion, an exploration of Athey’s career, refuses the linear narratives of art discourse and instead pays homage to the intensities of each mode of Athey’s performative practice and each community he engages." -- Publisher's website.
- Published
- 2019
9. Effects of salt and fat combinations on taste preference and perception
- Author
-
Bolhuis, Dieuwerke P., Newman, Lisa P., Keast, Russell S.J., Bolhuis, Dieuwerke P., Newman, Lisa P., and Keast, Russell S.J.
- Abstract
Fat and salt are a common and attractive combination in food and overconsumption of either is associated with negative health outcomes. The major aim was to investigate contributions and interactions of salt and fat on taste pleasantness and perception. The minor aim was to investigate individual fat taste sensitivity (detection threshold of oleic acid [C18:1]) on pleasantness for fat. In a complete factorial design, 49 participants (18-54 years, 12 males) tasted tomato soups with 4 different fat concentrations (0-20%) and 5 different salt concentrations (0.04-2.0%). The preferred concentration and the discrimination ability for both fat and salt were determined by ranking tests. Results show that salt and fat affected pleasantness separately (P < 0.01), with salt having the strongest effect. Fat concentrations 0%, 5%, and 10% did not differ in pleasantness, whereas 20% was less pleasant (P < 0.05). There were no interactions for fat and salt on pleasantness or saltiness and fattiness intensity. Fat taste sensitive participants preferred lower fat concentrations than less sensitive participants (P = 0.008). In conclusion, the strong effect of salt on pleasantness in this study suggests that salt, rather than fat, play a major role in the attraction to savory fatty foods.
- Published
- 2016
10. Dietary fat restriction increases fat taste sensitivity in people with obesity
- Author
-
Newman, Lisa P., Bolhuis, Dieuwerke P., Torres, Susan J., Keast, Russell S.J., Newman, Lisa P., Bolhuis, Dieuwerke P., Torres, Susan J., and Keast, Russell S.J.
- Abstract
OBJECTIVE: Individuals with obesity may be less sensitive to the taste of fat, and it is hypothesized that this is due to excess dietary fat intake. This study assessed the effect of a 6-week low-fat (LF) or portion control (PC) diet matched for weight loss on fat taste thresholds, fat perception, and preference in people with overweight/obesity. METHODS: Participants (n = 53) completed a randomized dietary intervention and consumed either a LF diet (25% fat) or PC diet (33% fat) for 6 weeks. Fat taste thresholds (lowest detectable fat concentration), fat perception (discrimination ability), preference, and anthropometry were assessed at baseline and week 6. RESULTS: Consumption of a LF diet (n = 26) and PC diet (n = 27) reduced participants' weight (P < 0.001), with no significant differences between groups (LF, -2.9%, PC, -2.7%). Both diets resulted in a decrease in fat taste thresholds (P = 0.014), and the effect tended to be stronger in the LF diet vs. the PC diet (P = 0.060). The ability to perceive different fat concentrations in foods was increased after the LF diet only (P = 0.017); however, food preference did not change on either diet. CONCLUSIONS: A PC and LF diet both increase fat taste sensitivity in people with overweight/obesity, with the strongest effect after the LF diet.
- Published
- 2016
11. Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer
- Author
-
Newman, Lisa A., Bensenhaver, Jessica M., Newman, Lisa A., and Bensenhaver, Jessica M.
- Published
- 2015
12. Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer / edited by Lisa A. Newman, Jessica M. Bensenhaver.
- Author
-
Newman, Lisa A. editor., Bensenhaver, Jessica M. editor., SpringerLink (Online service), Newman, Lisa A. editor., Bensenhaver, Jessica M. editor., and SpringerLink (Online service)
- Abstract
This volume reviews the evolution of information regarding the epidemiology of DCIS and its modes of detection, as well as treatment options as a function of both clinical trial data and ongoing investigational therapeutic prospects. Several of the challenging and clinically-relevant scenarios of DCIS that appear in daily practice is discussed, including the difficulties of distinguishing “true” DCIS from borderline patterns of other breast diseases and the therapeutic implications of differentiating these various diagnoses. Particular attention is paid to pathologic evaluation of DCIS, including histologic patterns and the importance of margin evaluation/margin control. The text also explores the data regarding DCIS in medical research in hereditary susceptibility for breast cancer and race/ethnicity-associated disparities in breast cancer. Written by experts in the field, Ductal Carcinoma In Situ and Microinvasive/Borderline Breast Cancer is a comprehensive, state-of-the art review of the field, and serves as a valuable resource for clinicians, surgeons and researchers with an interest in breast cancer.
- Published
- 2015
13. ATTENUATED ORAL FATTY ACID SENSITIVITY IS ASSOCIATED WITH ACUTE EXCESS ENERGY INTAKE
- Author
-
Keast, Russell, Azzopardi, K, Newman, Lisa, Haryono, R, Keast, Russell, Azzopardi, K, Newman, Lisa, and Haryono, R
- Published
- 2013
14. Oral fatty acid sensitivity and dietary fat consumption
- Author
-
Keast, Russell, Torres, Susan, Newman,Lisa P., Keast, Russell, Torres, Susan, and Newman,Lisa P.
- Abstract
Lisa investigated the taste of fat and its influence on excess fat consumption and obesity. This research established that taste sensitivity to fat can be modulated by fat intake and may be used as an obesity prevention tool in the future.
- Published
- 2013
15. Functionality of fatty acid chemoreception : a potential factor in the development of obesity?
- Author
-
Newman, Lisa, Haryono, Rivkeh, Keast, Russell, Newman, Lisa, Haryono, Rivkeh, and Keast, Russell
- Abstract
Excess dietary fat consumption is recognized as a strong contributing factor in the development of overweight and obesity. Understanding why some individuals are better than others at regulating fat intake will become increasingly important and emerging associative evidence implicates attenuated fatty acid sensing in both the oral cavity and gastrointestinal (GI) tract in the development of obesity. Functional implications of impaired fatty acid chemoreception include diminished activation of the gustatory system, the cephalic response and satiety. This review will focus on knowledge from animal and human studies supporting the existence of oral fatty acid chemoreception including putative oral detection mechanisms, and how sensitivity to fatty acids is associated with fat consumption and fatty food preference.
- Published
- 2013
16. African ancestry and higher prevalence of triple-negative breast cancer
- Author
-
Department of Pathology, University of Michigan, Ann Arbor, Michigan, University of Michigan Medical School, Ann Arbor, Michigan, University of Michigan Medical School, Ann Arbor, Michigan ; Breast Care Center, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan ; Department of Surgery, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, University of Michigan Medical School, Ann Arbor, Michigan ; Breast Care Center, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan ; Department of Surgery, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 647-9647 ; Director, Breast Care Center, Professor, Department of Surgery, University of Michigan, 1500 E. Medical Center Drive, 3308 Cancer Center, Ann Arbor, MI 48109-0932, Department of Pathology, Ford Health System, Detroit, Michigan ; Center for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, School of Public Health, University of Illinois, Chicago, Illinois, Komfo Anokye Teaching Hospital, Kumasi, Ghana, Department of Pathology, Ford Health System, Detroit, Michigan, Stark, Azadeh, Kleer, Celina G., Martin, Iman, Awuah, Baffour, Nsiah-Asare, Anthony, Takyi, Valerie, Braman, Maria, E. Quayson, Solomon, Zarbo, Richard, Wicha, Max, Newman, Lisa, Department of Pathology, University of Michigan, Ann Arbor, Michigan, University of Michigan Medical School, Ann Arbor, Michigan, University of Michigan Medical School, Ann Arbor, Michigan ; Breast Care Center, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan ; Department of Surgery, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan, University of Michigan Medical School, Ann Arbor, Michigan ; Breast Care Center, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan ; Department of Surgery, Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan ; Fax: (734) 647-9647 ; Director, Breast Care Center, Professor, Department of Surgery, University of Michigan, 1500 E. Medical Center Drive, 3308 Cancer Center, Ann Arbor, MI 48109-0932, Department of Pathology, Ford Health System, Detroit, Michigan ; Center for Clinical Epidemiology and Biostatistics, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, School of Public Health, University of Illinois, Chicago, Illinois, Komfo Anokye Teaching Hospital, Kumasi, Ghana, Department of Pathology, Ford Health System, Detroit, Michigan, Stark, Azadeh, Kleer, Celina G., Martin, Iman, Awuah, Baffour, Nsiah-Asare, Anthony, Takyi, Valerie, Braman, Maria, E. Quayson, Solomon, Zarbo, Richard, Wicha, Max, and Newman, Lisa
- Abstract
BACKGROUND: The study of breast cancer in women with African ancestry offers the promise of identifying markers for risk assessment and treatment of triple-negative disease. METHODS: African American and white American women with invasive cancer diagnosed at the Henry Ford Health System comprised the primary study population, and Ghanaian patients diagnosed and/or treated at the Komfo Anokye Teaching Hospital in Kumasi, Ghana constituted the comparison group. Formalin-fixed, paraffin-embedded specimens were transported to the University of Michigan for histopathology confirmation, and assessment of estrogen and progesterone receptors and HER-2/ neu expression. RESULTS: The study population included 1008 white Americans, 581 African Americans, and 75 Ghanaians. Mean age at diagnosis was 48.0 years for Ghanaian, 60.8 years for African American, and 62.4 for white American cases ( P = .002). Proportions of Ghanaian, African American, and white American cases with estrogen receptor-negative tumors were 76%, 36%, and 22%, respectively ( P < .001), and proportions with triple-negative disease were 82%, 26%, and 16%, respectively ( P < .001). All Ghanaian cases were palpable, locally advanced cancers; 57 (76%) were grade 3. A total of 147 American women were diagnosed as stage III or IV; of these, 67.5% (n = 46) of African Americans and 44.6% (n = 29) of white Americans were grade 3. Among palpable, grade 3 cancers, Ghanaians had the highest prevalence of triple-negative tumors (82.2%), followed by African Americans (32.8%) and white Americans (10.2%). CONCLUSIONS: Our study demonstrates progressively increasing frequency of estrogen receptor-negative and triple-negative tumors among breast cancer patients with white American, African American, and Ghanaian/African backgrounds. This pattern indicates a need for additional investigations correlating the extent of African ancestry and high-risk breast cancer subtypes. Cancer 2010. ?? 2010 American Cancer Society.
- Published
- 2010
17. Perceptions of Clinical Research Participation among African American Women
- Author
-
Smith, Yolanda R., Johnson, Angela M., Newman, Lisa A., Greene, Ardeth, Johnson, Timothy R. B., Rogers, Juliet L., Smith, Yolanda R., Johnson, Angela M., Newman, Lisa A., Greene, Ardeth, Johnson, Timothy R. B., and Rogers, Juliet L.
- Abstract
Background: Recruiting minority women into clinical research remains a significant challenge to conducting ethnically representative research. The main objective of this Office on Women's Health, DHHS-funded e-health database evaluation project was to examine African American women 's thoughts and perceptions about the clinical research process and about participation in the University of Michigan Women's Health Registry research database. Methods: Thirty-one African American women were recruited from the community to participate in a total of five 90-minute focus group discussions. All sessions were audiotaped and transcribed verbatim. Thematic content analysis was used to identify relevant themes about participation in clinical research and the Women's Health Registry. Results: Ten common trends were identified. (1) Information about the Women's Health Registry is not reaching the community. (2) Research is perceived as biased to benefit Caucasians. (3) Community involvement by the research team is critical for trust to develop. (4) Research directly relevant to African Americans or their community will encourage participation. (5) Researchers should use existing networks and advertise in appropriate locations. (6) The community needs more information concerning research. (7) Compensation is important. (8) Research that addresses a personal or family medical problem encourages involvement. (9) Minority representation on the research team is a motivator to participation. (10) There is limited time for healthcare-related activities. Conclusions: Successful recruitment strategies for African American women should feature community-based, culturally appropriate approaches. Online research databases for subject recruitment will likely be successful only if implemented within a broader community-oriented program.
- Published
- 2009
- Full Text
- View/download PDF
18. Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy Presented in part at the Annual Meeting of the American Society of Clinical Oncology, Atlanta, Georgia, June 2???6, 2006.
- Author
-
Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, Department Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, Division of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston Texas, Department Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas ; Fax: (713) 792-4689 ; Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, Jeruss, Jacqueline S., Newman, Lisa A., Ayers, Gregory D., Cristofanilli, Massimo, Broglio, Kristine R., Meric-Bernstam, Funda, Yi, Min, Waljee, Jennifer F., Ross, Merrick I., Hunt, Kelly K., Department of Surgery, University of Michigan Medical School, Ann Arbor, Michigan, Department Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, Division of Quantitative Sciences, The University of Texas M. D. Anderson Cancer Center, Houston Texas, Department Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas ; Fax: (713) 792-4689 ; Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 444, Houston, TX 77030, Jeruss, Jacqueline S., Newman, Lisa A., Ayers, Gregory D., Cristofanilli, Massimo, Broglio, Kristine R., Meric-Bernstam, Funda, Yi, Min, Waljee, Jennifer F., Ross, Merrick I., and Hunt, Kelly K.
- Abstract
BACKGROUND. The utility of sentinel lymph node (SNL) biopsy (SLNB) as a predictor of axillary lymph node status is similar in patients who receive neoadjuvant chemotherapy and patients who undergo surgery first. The authors of this study hypothesized that patients with positive SLNs after neoadjuvant therapy would have unique clinicopathologic factors that would be predictive of additional positive non-SLNs distinct from patients who underwent surgery first. METHODS. One hundred four patients were identified who received neoadjuvant chemotherapy, had a positive SLN, and underwent axillary dissection between 1997 and 2005. At the time of presentation, 66 patients had clinically negative lymph nodes by ultrasonography, and 38 patients had positive lymph nodes confirmed by fine-needle aspiration. Eighteen factors were assessed for their ability to predict positive non-SLNs using chi-square and logistic regression analysis with a bootstrapped, backwards elimination procedure. The resulting nomogram was tested by using a patient cohort from another institution. RESULTS. Patients with clinically negative lymph nodes at presentation were less likely than patients with positive lymph nodes to have positive non-SLNs (47% vs 71%; P = .017). On multivariate analysis, lymphovascular invasion, the method for detecting SLN metastasis, multicentricity, positive axillary lymph nodes at presentation, and pathologic tumor size retained grouped significance with a bootstrap-adjusted area under the curve (AUC) of 0.762. The resulting nomogram was validated in the external patient cohort (AUC, 0.78). CONCLUSIONS. A significant proportion of patients with positive SLNs after neoadjuvant chemotherapy had no positive non-SLNs. The use of a nomogram based on 5 predictive variables that were identified in this study may be useful for predicting the risk of positive non-SLNs in patients who have positive SLNs after chemotherapy. Cancer 2008. ?? 2008 American Cancer Society.
- Published
- 2008
19. Sentinel lymph node biopsy for breast cancer: How many nodes are enough?
- Author
-
Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan ; 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0932; Fax: 734-647-9647., Department of Surgery, Mayo Clinic, Rochester, Minnesota, Zakaria, Shaheen, Degnim, Amy C., Kleer, Celina G., Diehl, Kathleen A., Cimmino, Vincent M., Chang, Alfred E., Newman, Lisa A., Sabel, Michael S., Department of Pathology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, Department of Surgery, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan ; 3304 Cancer Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0932; Fax: 734-647-9647., Department of Surgery, Mayo Clinic, Rochester, Minnesota, Zakaria, Shaheen, Degnim, Amy C., Kleer, Celina G., Diehl, Kathleen A., Cimmino, Vincent M., Chang, Alfred E., Newman, Lisa A., and Sabel, Michael S.
- Abstract
Introduction Sentinel lymph node (SLN) biopsy using blue dye and radioisotope often results in the removal of multiple SLNs. We sought to determine whether there is a point where the surgeon can terminate the procedure without sacrificing accuracy. Methods One thousand one hundred ninety-seven patients from University of Michigan and the Mayo Clinic undergoing SLN biopsy formed the study population. Surgeons removed all SLNs until counts within the axilla were less than 10% of the highest node ex vivo and recorded the order in which they were removed. Results The mean number of SLNs removed per patient was 2.5 (range 1–9). Approximately 42% of patients had three or more lymph nodes removed, while 19% had four or more lymph nodes removed. Eighteen percent of patients (132/725) at University of Michigan and 22% (103/472) at Mayo Clinic had a positive SLN. Ninety-eight percent (231/235) of patients with lymph node metastases were identified by the 3rd SLN while 100% were identified by the 4th SLN. Conclusion Among patients undergoing SLN biopsy for breast cancer, the only positive SLN is rarely identified in the 4th or higher node. Terminating the procedure at the 4th node may lower the cost of the procedure and reduce morbidity. J. Surg. Oncol. 2007;96:554–559. © 2007 Wiley-Liss, Inc.
- Published
- 2007
20. Projecting Individualized Absolute Invasive Breast Cancer Risk in African American Women
- Author
-
Gail, Mitchell H., Gail, Mitchell H., Costantino, Joseph P., Pee, David, Bondy, Melissa, Newman, Lisa, Selvan, Mano, Anderson, Garnet L., Malone, Kathleen E., Marchbanks, Polly A., McCaskill-Stevens, Worta, Norman, Sandra A., Simon, Michael S., Spirtas, Robert, Ursin, Giske, Bernstein, Leslie, Gail, Mitchell H., Gail, Mitchell H., Costantino, Joseph P., Pee, David, Bondy, Melissa, Newman, Lisa, Selvan, Mano, Anderson, Garnet L., Malone, Kathleen E., Marchbanks, Polly A., McCaskill-Stevens, Worta, Norman, Sandra A., Simon, Michael S., Spirtas, Robert, Ursin, Giske, and Bernstein, Leslie
- Abstract
Background The Breast Cancer Risk Assessment Tool of the National Cancer Institute (NCI) is widely used for counseling and determining eligibility for breast cancer prevention trials, although its validity for projecting risk in African American women is uncertain. We developed a model for projecting absolute risk of invasive breast cancer in African American women and compared its projections with those from the Breast Cancer Risk Assessment Tool. Methods Data from 1607 African American women with invasive breast cancer and 1647 African American control subjects in the Women’s Contraceptive and Reproductive Experiences (CARE) Study were used to compute relative and attributable risks that were based on age at menarche, number of affected mother or sisters, and number of previous benign biopsy examinations. Absolute risks were obtained by combining this information with data on invasive breast cancer incidence in African American women from the NCI’s Surveillance, Epidemiology and End Results Program and with national mortality data. Eligibility screening data from the Study of Tamoxifen and Raloxifene (STAR) trial were used to determine how the new model would affect eligibility, and independent data from the Women’s Health Initiative (WHI) were used to assess how well numbers of invasive breast cancers predicted by the new model agreed with observed cancers. Results Tables and graphs for estimating relative risks and projecting absolute invasive breast cancer risk with confidence intervals were developed for African American women. Relative risks for family history and number of biopsies and attributable risks estimated from the CARE population were lower than those from the Breast Cancer Risk Assessment Tool, as was the discriminatory accuracy (i.e., concordance). Using eligibility screening data from the STAR trial, we estimated that 30.3% of African American women would have had 5-year invasive breast cancer risks of at least 1.66% by use of the CARE model, com
- Published
- 2007
21. Lymphatic Mapping and Sentinel Lymph Node Biopsy for Patients With Local Recurrence After Breast-Conservation Therapy
- Author
-
Department of Radiology/Nuclear Medicine, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Department of Surgery, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Ann Arbor, Newman, Erika A., Chang, Alfred E., Newman, Lisa A., Frey, Kirk A., Diehl, Kathleen M., Cimmino, Vincent M., Sabel, Michael S., Department of Radiology/Nuclear Medicine, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Department of Surgery, Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Ann Arbor, Newman, Erika A., Chang, Alfred E., Newman, Lisa A., Frey, Kirk A., Diehl, Kathleen M., Cimmino, Vincent M., and Sabel, Michael S.
- Abstract
Local recurrence (LR) after breast-conservation therapy for breast cancer occurs in 10% to 15% of cases. A subset of these represents biologically aggressive disease, yet prognostic features for identifying this high-risk category are lacking. We hypothesized that lymphatic mapping and sentinel lymph node biopsy would provide useful information regarding dominant lymphatic drainage patterns of patients with LR.
- Published
- 2006
22. Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy
- Author
-
Hematology/Oncology Division, Department of Internal Medicine, University of Michigan, USA; Anne F. Schott, MD, 1500 E. Medical Center Drive, C354 MIB, 48109-0848, Ann Arbor, MI, USA, Department of Radiology, University of Michigan, USA, Hematology/Oncology Division, Department of Internal Medicine, University of Michigan, USA, Department of Pathology, University of Michigan, USA, Department of Surgery, University of Michigan, USA, Department of Radiation Oncology, University of Michigan, USA, Comprehensive Cancer Center, University of Michigan, USA, School of Public Health, University of Michigan, USA, Henry Ford Hospital, USA, Ann Arbor, Hunt, Karen A., Baker, Laurence H., Newman, Lisa A., Griffith, Kent A., Roubidoux, Marilyn A., Schott, Anne F., Helvie, Mark A., Hayes, Daniel F., Kleer, Celina G., Pierce, Lori J., Murray, Susan, Paramagul, Chintana, Hematology/Oncology Division, Department of Internal Medicine, University of Michigan, USA; Anne F. Schott, MD, 1500 E. Medical Center Drive, C354 MIB, 48109-0848, Ann Arbor, MI, USA, Department of Radiology, University of Michigan, USA, Hematology/Oncology Division, Department of Internal Medicine, University of Michigan, USA, Department of Pathology, University of Michigan, USA, Department of Surgery, University of Michigan, USA, Department of Radiation Oncology, University of Michigan, USA, Comprehensive Cancer Center, University of Michigan, USA, School of Public Health, University of Michigan, USA, Henry Ford Hospital, USA, Ann Arbor, Hunt, Karen A., Baker, Laurence H., Newman, Lisa A., Griffith, Kent A., Roubidoux, Marilyn A., Schott, Anne F., Helvie, Mark A., Hayes, Daniel F., Kleer, Celina G., Pierce, Lori J., Murray, Susan, and Paramagul, Chintana
- Abstract
To prospectively compare the ability of clinical examination, mammography, vascularity-sensitive ultrasound, and magnetic resonance imaging (MRI) to determine pathologic complete response (CR) in breast cancer patients undergoing neoadjuvant chemotherapy.
- Published
- 2006
23. Clinicopathologic Features Associated With Having Four or More Metastatic Axillary Nodes in Breast Cancer Patients With a Positive Sentinel Lymph Node
- Author
-
Department of Biostatistics, University of Michigan Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Department of Surgery, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, 3308 Cancer Center, Ann Arbor, Michigan, 48109-0932, Department of Pathology, University of Michigan Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Department of Surgery, St. Joseph???s Hospital and Medical Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109; Department of Biostatistics, University of Michigan Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, Department of Surgery, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, Ann Arbor, Sabel, Michael S., Griffith, Kent A., Rivers, Aeisha K., Chang, Alfred E., Degnim, Amy C., Cimmino, Vincent M., Hunt, Kelly K., Diehl, Kathleen M., Newman, Lisa A., Lucas, Peter C., Department of Biostatistics, University of Michigan Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Department of Surgery, University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, 3308 Cancer Center, Ann Arbor, Michigan, 48109-0932, Department of Pathology, University of Michigan Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Department of Surgery, St. Joseph???s Hospital and Medical Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109; Department of Biostatistics, University of Michigan Comprehensive Cancer Center, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, Michigan, 48109, Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, Minnesota, 55905, Department of Surgery, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, Ann Arbor, Sabel, Michael S., Griffith, Kent A., Rivers, Aeisha K., Chang, Alfred E., Degnim, Amy C., Cimmino, Vincent M., Hunt, Kelly K., Diehl, Kathleen M., Newman, Lisa A., and Lucas, Peter C.
- Abstract
The survival benefit of a completion axillary lymph node dissection (ALND) in patients after removal of a metastatic sentinel lymph node (SLN) is uncertain and is under study in ongoing clinical trials. The completion ALND remains necessary, however, for the identification of cases with at least four metastatic lymph nodes, in which extended-field locoregional and/or postmastectomy radiation will be recommended. Our goal was evaluate clinicopathologic features that might serve as surrogates for determining which patients with a positive SLN are likely or unlikely to belong to this high-risk subset.
- Published
- 2006
24. Efficacy of sentinel lymph node biopsy in male breast cancer
- Author
-
Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan ; Division of Surgical Oncology, University of Michigan, 3214 Cancer Center, 1500, East Medical Center Drive, Ann Arbor, MI 48109-0932. Fax: (734) 647-9647., Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, Cimmino, Vincent M., Degnim, Amy C., Sabel, Michael S., Diehl, Kathleen M., Newman, Lisa A., Chang, Alfred E., Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan ; Division of Surgical Oncology, University of Michigan, 3214 Cancer Center, 1500, East Medical Center Drive, Ann Arbor, MI 48109-0932. Fax: (734) 647-9647., Division of Surgical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, Cimmino, Vincent M., Degnim, Amy C., Sabel, Michael S., Diehl, Kathleen M., Newman, Lisa A., and Chang, Alfred E.
- Abstract
Background Sentinel lymph node biopsy (SLNB) is rapidly becoming the standard of care in the treatment of women with early stage breast cancer. Male breast cancer although relatively rare, has typically been treated with mastectomy and axillary lymph node dissection (ALND). Men who develop breast carcinoma have the same risk as their female counterparts of developing the morbidities associated with axillary dissection. SLNB has been championed as a procedure aimed at preventing those morbidities. We recently have evaluated the role of SLNB in the treatment of men with early stage breast cancer. Methods Among the 18 men treated at the University of Michigan Medical Center for breast cancer from May 1998 to November 2002, 6 were treated with SLNB. Results The mean tumor size was 1.6 cm. The mean patient age was 59.8 years. All of the patients had one or more sentinel lymph nodes identified. Two of the six did not have confirmatory axillary dissection. Three of the six had positive sentinel lymph nodes (50%). Only one of the three patients with a positive sentinel node had more nodes positive. One of the six patients had a positive node on frozen section and underwent immediate complete axillary dissection. This patient had no additional positive nodes. No patients in our series had immunohistochemical studies of the lymph nodes. Conclusions Men with early stage breast carcinoma may be offered the management option of SLNB since in the hands of experienced surgeons it has a success rate apparently equal to that in their female counterparts. J. Surg. Oncol. 2004;86:74-77. © 2004 Wiley-Liss, Inc.
- Published
- 2006
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.